These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 34655161

  • 1. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
    Otsubo K, Sakai H, Kimura H, Miyazawa T, Marushima H, Kojima K, Furuya N, Mineshita M, Chosokabe M, Koike J, Saji H.
    Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
    [Abstract] [Full Text] [Related]

  • 2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 3. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.
    Mod Pathol; 2020 Feb 01; 33(2):303-311. PubMed ID: 31537897
    [Abstract] [Full Text] [Related]

  • 4. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
    Clin Lung Cancer; 2019 Sep 01; 20(5):e564-e575. PubMed ID: 31279641
    [Abstract] [Full Text] [Related]

  • 5. Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma.
    Okita R, Senoo T, Mimura-Kimura Y, Mimura Y, Murakami T, Ikeda E, Okada M, Inokawa H, Aoe K.
    Sci Rep; 2024 Jul 10; 14(1):15947. PubMed ID: 38987362
    [Abstract] [Full Text] [Related]

  • 6. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status.
    Rrapaj E, Giacometti L, Spina P, Salvo M, Baselli GA, Veggiani C, Rena O, Trisolini E, Boldorini RL.
    Pathology; 2021 Jun 10; 53(4):462-469. PubMed ID: 33272690
    [Abstract] [Full Text] [Related]

  • 7. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun 10; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 8. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
    Passiglia F, Bironzo P, Righi L, Listì A, Arizio F, Novello S, Volante M, Scagliotti GV.
    Clin Lung Cancer; 2021 Jan 10; 22(1):e63-e66. PubMed ID: 32917522
    [Abstract] [Full Text] [Related]

  • 9. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S.
    Asia Pac J Clin Oncol; 2018 Feb 10; 14(1):69-73. PubMed ID: 29105302
    [Abstract] [Full Text] [Related]

  • 10. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
    Babacan NA, Pina IB, Signorelli D, Prelaj A, Garassino MC, Tanvetyanon T.
    Clin Lung Cancer; 2020 Sep 10; 21(5):e456-e463. PubMed ID: 32265109
    [Abstract] [Full Text] [Related]

  • 11. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E.
    Lung Cancer; 2016 Jun 10; 96():1-6. PubMed ID: 27133741
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G.
    Hum Pathol; 2019 May 10; 87():11-17. PubMed ID: 30794891
    [Abstract] [Full Text] [Related]

  • 15. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.
    J Thorac Oncol; 2017 Sep 10; 12(9):1421-1433. PubMed ID: 28629895
    [Abstract] [Full Text] [Related]

  • 16. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.
    PLoS One; 2015 Sep 10; 10(3):e0121071. PubMed ID: 25774992
    [Abstract] [Full Text] [Related]

  • 17. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M.
    Hum Pathol; 2018 Jan 10; 71():1-7. PubMed ID: 28811252
    [Abstract] [Full Text] [Related]

  • 18. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV.
    J Thorac Oncol; 2018 Jan 10; 13(1):124-133. PubMed ID: 29079455
    [Abstract] [Full Text] [Related]

  • 19. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E, Kajino K, Abe M, Ohtsuji N, Saeki H, Hlaing MT, Hino O.
    Pathol Int; 2020 Dec 10; 70(12):999-1008. PubMed ID: 33027549
    [Abstract] [Full Text] [Related]

  • 20. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D.
    Mol Biol Rep; 2019 Jun 10; 46(3):2713-2720. PubMed ID: 30840203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.